Lower Level of MAPK Expression Is Associated with Anthracycline Resistance and Decreased Survival in Patients with Hormone Receptor Negative Breast Cancer-Reference-Cited by-同舟云学术

Lower Level of MAPK Expression Is Associated with Anthracycline Resistance and Decreased Survival in Patients with Hormone Receptor Negative Breast Cancer

Published:2008-01 Issue:7 Volume:26 Page:671-679
ISSN:0735-7907
Container-title:Cancer Investigation
language:en
Short-container-title:Cancer Investigation

Author:

Derin Duygu,Eralp Yesim,Ozluk Yasemin,Yavuz Ekrem,Guney Nese,Saip Pinar,Igci Abdullah,Ozmen Vahit,Kücücük Seden,Aslay Isik,Aydiner Adnan,Topuz Erkan

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1080/07357900801891628

Reference42 articles.

1. Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary node metastasis, and histopathologic grading

2. Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers

3. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

4. Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma

5. Breast cancer classification and prognosis based on gene expression profiles from a population-based study

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transformation of nomifensine using ionizing radiation and exploration of its anticancer effects in MCF‑7 cells;Experimental and Therapeutic Medicine;2022-02-23

2. Sorafenib-Loaded Long-Circulating Nanoliposomes for Liver Cancer Therapy;BioMed Research International;2020-05-07

3. Metabolic gene alterations impact the clinical aggressiveness and drug responses of 32 human cancers;Communications Biology;2019-11-14

4. Identification of dysregulated miRNAs in triple negative breast cancer: A meta‐analysis approach;Journal of Cellular Physiology;2018-11-29

5. Adaptive Estimation of Personalized Maximum Tolerated Dose in Cancer Phase I Clinical Trials Based on All Toxicities and Individual Genomic Profile;PLOS ONE;2017-01-26